MTOR and B-cell chronic lymphocytic leukemia: Interestingly, there were three kinds of compounds which could inhibit the mTOR pathway and CDKs in CLL, respectively, and these have been researched in CLL before and CDK inhibitors have entered clinical trials in patients with relapsed or refractory chronic lymphocytic leukemia.